ArticleFrontiers in oncology2026
Risk factors for postoperative pulmonary complications in esophageal cancer: focus on inflammatory markers.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with esophageal cancer (EC), postoperative pulmonary complications (PPCs) have an impact on both the long-term prognosis and postoperative recovery. The prognostic utility of novel inflammatory biomarkers for PPCs is yet unknown, despite the fact that systemic inflammation is a hallmark of malignancy. The objective of this study was to methodically identify perioperative parameters that are independently linked to the formation of PPCs, with an emphasis on inflammatory markers. Methods: 781 individuals receiving elective EC resection between January 2022 and December 2024 were included in this retrospective, single-center cohort analysis. Patients were divided into two groups at random: a validation set (n = 232) and a training set (n = 549). To find independent factors linked to PPCs, univariate and multivariate logistic regression analyses were carried out. A nomogram based on the factors found was created for exploratory purposes, and its effectiveness was evaluated. Results: 11.7% of people had PPCs overall. Five independent predictors were found by multivariate analysis: the eosinophil count (OR = 5.924, p=0.027), intraoperative pleural metastasis (OR = 6.853, p=0.026), postoperative ICU admission(OR = 6.963, p=0.006), and postoperative anastomotic leakage (OR = 13.454, p=0.000) were found to be significant risk factors, while the LMR (OR = 0.791, p=0.021) was a protective factor. Limited discriminative ability was demonstrated by the exploratory nomogram based on these parameters (AUC 0.665 in training, 0.561 in validation sets). With modified C-statistics of 0.666 and 0.557 for the training and validation sets, respectively, the DCA showed acceptable discriminatory performance. The DCA revealed a clinically net advantage throughout a broad range of threshold probabilities, and the model demonstrated satisfactory calibration (Hosmer-Lemeshow test p>0.05). Conclusion: Clinical parameters and inflammatory biomarkers are identified as independent risk factors for PPCs in EC patients. Higher LMR is a protective factor for PPCs, while postoperative ICU admission, higher eosinophil counts, intraoperative pleural metastases, and postoperative anastomotic leaks are risk factors. In order to lower the incidence of PPC, these results offer a theoretical foundation for clinical risk classification and focused preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.